[April 14, 2014]

Research and Markets: Global Cariprazine Use for Schizophrenia - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/5z4vzf/cariprazine) has announced the addition of the "Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.

Cariprazine is a D3-preferring D3/D2 receptor partial agonist under development for the treatment of schizophrenia, bipolar mania, and major depressive disorder by Hungary-based Gedeon Richter and Forest. While maintainig highest affinity for D3 receptors, cariprazine also has low potency at 5-HT2C, H1, and adrenergic receptor sites.

Scope

• Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Cariprazine for the top seven countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Key Topics Covered:

1. Tables & Figures
2. Introduction
3. Disease Overview
4. Disease Management
5. Competitive Assessment
6. Opportunity and Unmet Need
7. Pipeline Assessment
8. Cariprazine
9. Appendix

For more information visit http://www.researchandmarkets.com/research/5z4vzf/cariprazine

[ Back To TMCnet.com's Homepage ]